Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
multiple myeloma
Pharma
EHA: Gearing up for US comeback, GSK details Blenrep's PFS win
If approved next month, the drug would complete a return to the U.S. market after it was withdrawn following a failed confirmatory study in 2022.
Zoey Becker
Jun 12, 2025 9:25am
Sanofi's Sarclisa SC, delivered by on-body injector, matches IV
Jun 3, 2025 8:15am
FDA advisors back Darzalex as treatment for early myeloma
May 21, 2025 8:52am
GSK kicks off Blenrep's market return with first combo nod in UK
Apr 17, 2025 2:29pm
J&J, Legend to invest $150M in Belgium cell therapy facility
Mar 12, 2025 2:15pm
BMS buys cell therapy partner 2seventy bio for $286M
Mar 11, 2025 10:12am
